Arizona State University

Oncomyx Therapeutics, Inc.

Nancy Yaneth Villa

Douglas Grant McFadden

Mohammed Masmudur Rahman

Lino Torres-Dominguez

Lina Franco Achury

Leslie Lynne Sharp

Joseph Blattman

John Christie

Disclosed herein, in certain embodiments, are recombinant myxoma viruses (MYXVs) and nucleic acid constructs encoding the recombinant MYXVs. In some embodiments, the MYXVs are engineered to inactivate or attenuate an activity or expression level of an M153 protein. In some embodiments, the MYXVs are engineered to express one or more transgenes such as a tumor necrosis factor (TNF), interleukin-12 (IL-12), or decorin. Also disclosed herein, in certain embodiments, are methods of using the MYXVs. Some embodiments include providing a MYXV as described herein to a subject in need thereof.

Oncolytic virus platform to treat cancers with myxoma virus

Disclosed herein, in certain embodiments, is a method of inhibiting or treating a cancer with use of a TNF expressing myxoma virus. Also disclosed herein are methods of inhibiting or treating a cancer with use of a mononuclear peripheral blood cells and/or a bone marrow cells treated with a TNF-expressing myxoma virus. Some aspects relate to engineered myxoma virus and pharmaceutical compositions for use with one or more of the methods described herein.

Methods of treating cancer with TNF expressing myxoma virus

Growing community of inventors

Scottsdale, AZ, United States of America

Nancy Yaneth Villa